Product Collaboration
Seattle Genetics entered into a collaboration with Millennium: The Takeda Oncology Company in December 2009 for the global development and commercialization of brentuximab vedotin (SGN-35). Under the agreement, Seattle Genetics retained rights to commercialize brentuximab vedotin in the United States and Canada. Millennium has exclusive rights to commercialize the product candidate in the rest of the world. Seattle Genetics received an upfront payment of $60 million, and is eligible to receive progress-dependent milestone payments that could total more than $230 million and tiered double-digit royalties on sales of brentuximab vedotin within Millennium's licensed territories. Seattle Genetics and Millennium will jointly fund worldwide development costs on a 50:50 basis, except in Japan where Millennium/Takeda is fully responsible for development costs. Development funding provided by Millennium over the first three years of the collaboration is expected to be at least $75 million.

Antibody-Drug Conjugate Collaborations
Seattle Genetics has licensed its antibody-drug conjugate (ADC) technology to a number of industry-leading biotechnology and pharmaceutical companies for use with their proprietary monoclonal antibodies. These collaborations include upfront cash payments to Seattle Genetics, milestones and royalties on net sales of products incorporating Seattle Genetics' ADC technology. The licensees are responsible for development, manufacturing and commercialization of any ADC product candidates that result from the collaborations.

Co-Development Agreement
Seattle Genetics has an ADC co-development agreement with Agensys, a wholly-owned subsidiary of Astellas Pharma. Under the agreement, Agensys is providing proprietary targets and monoclonal antibodies to be utilized with Seattle Genetics' proprietary ADC technology. The companies are sharing research and development costs on up to three ADC products, and would share equally in any profits. The initial co-development program under the collaboration is ASG-5ME for solid tumors, which is expected to advance into clinical trials during 2010.

Collaboration Opportunities
If you are interested in learning more about ADC or SEA technology licensing or product partnering opportunities, please contact our Business Development team at businessdevelopment@seagen.com, or by calling (425) 527-4000.